Literature DB >> 28586782

Are Cystic Pancreatic Neuroendocrine Tumors an Indolent Entity Results from a Single-Center Surgical Series.

Salvatore Paiella, Giovanni Marchegiani, Marco Miotto, Anna Malpaga, Harmony Impellizzeri, Greta Montagnini, Tommaso Pollini, Chiara Nessi, Giovanni Butturini, Paola Capelli, Ilaria Posenato, Aldo Scarpa, Mirko D'Onofrio, Riccardo De Robertis, Sara Cingarlini, Letizia Boninsegna, Claudio Bassi, Roberto Salvia, Luca Landoni.   

Abstract

INTRODUCTION: Cystic pancreatic neuroendocrine tumors (CPanNETs) represent an uncommon variant of pancreatic neuroendocrine tumors (PanNETs). Due to their rarity, there is a lack of knowledge with regard to clinical features and postoperative outcome.
METHODS: The prospectively maintained surgical database of a high-volume institution was queried, and 46 resected CPanNETs were detected from 1988 to 2015. Clinical, demographic, and pathological features and survival outcomes of CPanNETs were described and matched with a population of 92 solid PanNETs (SPanNETs) for comparison.
RESULTS: CPanNETs accounted for 7.8% of the overall number of resected PanNETs (46/587). CPanNETs were mostly sporadic (n = 42, 91%) and nonfunctioning (39%). Two functioning CPanNETs were detected (4.3%), and they were 2 gastrinomas. The median tumor diameter was 30 mm (range 10-120). All tumors were well differentiated, with 38 (82.6%) G1 and 8 (17.4%) G2 tumors. Overall, no CPanNET showed a Ki-67 >5%. A correct preoperative diagnosis of a CPanNET was made in half of the cases. After a median follow-up of >70 months, the 5- and 10-year overall survival of resected CPanNETs was 93.8 and 62.5%, respectively, compared to 92.7 and 84.6% for SPanNETs (p > 0.05). The 5- and 10-year disease-free survival rates were 94.5 and 88.2% for CPanNETs and 81.8 and 78.9% for SPanNETs, respectively (p > 0.05).
CONCLUSION: In the setting of a surgical cohort, CPanNETs are rare, nonfunctional, and well-differentiated neoplasms. After surgical resection, they share the excellent outcome of their well-differentiated solid counterparts for both survival and recurrence.
© 2017 S. Karger AG, Basel.

Entities:  

Keywords:  Clinical features; Cystic pancreatic neuroendocrine tumors; Postoperative outcome; Single-center surgical series; Solid pancreatic neuroendocrine tumors

Mesh:

Year:  2017        PMID: 28586782     DOI: 10.1159/000477849

Source DB:  PubMed          Journal:  Neuroendocrinology        ISSN: 0028-3835            Impact factor:   4.914


  6 in total

Review 1.  Systematic Review and Metaanalysis of Lymph Node Metastases of Resected Pancreatic Neuroendocrine Tumors.

Authors:  Masayuki Tanaka; Max Heckler; André L Mihaljevic; Pascal Probst; Ulla Klaiber; Ulrike Heger; Simon Schimmack; Markus W Büchler; Thilo Hackert
Journal:  Ann Surg Oncol       Date:  2020-07-27       Impact factor: 5.344

Review 2.  Imaging of pancreatic neuroendocrine tumors: recent advances, current status, and controversies.

Authors:  Lingaku Lee; Tetsuhide Ito; Robert T Jensen
Journal:  Expert Rev Anticancer Ther       Date:  2018-07-17       Impact factor: 4.512

Review 3.  Prognostic and predictive factors on overall survival and surgical outcomes in pancreatic neuroendocrine tumors: recent advances and controversies.

Authors:  Lingaku Lee; Tetsuhide Ito; Robert T Jensen
Journal:  Expert Rev Anticancer Ther       Date:  2019-11-27       Impact factor: 4.512

4.  Basic Pancreatic Lesions: Radiologic-pathologic Correlation.

Authors:  Yun Bian; Hui Jiang; Jianming Zheng; Chengwei Shao; Jianping Lu
Journal:  J Transl Int Med       Date:  2022-04-02

5.  A single-center experience with pancreatic cystic neuroendocrine tumors.

Authors:  Ange Khalil; Jacques Ewald; Ugo Marchese; Aurélie Autret; Jonathan Garnier; Patricia Niccoli; Gilles Piana; Flora Poizat; Marc Giovannini; Jean-Robert Delpero; Olivier Turrini
Journal:  World J Surg Oncol       Date:  2020-08-15       Impact factor: 2.754

Review 6.  Cystic pancreatic lesions: MR imaging findings and management.

Authors:  Giovanni Morana; Pierluigi Ciet; Silvia Venturini
Journal:  Insights Imaging       Date:  2021-08-10
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.